Danish Veterinary Institute Copenhagen, Denmark
|
|
- Constance Rose
- 6 years ago
- Views:
Transcription
1 Pasteur, Health, Results from EQAS the External Quality Assurance System 2002 of the WHO Global Salmonella and Laboratory Support Project (Global Salm-Surv) Petersen A., Aarestrup F. M., Jensen A. B., Lo Fo Wong D., Evans M. C., Angulo F., Imhoff B., Binsztein N, Braam P., Jouan M., Wegener H. C. and Seyfarth A.M. February 2003 Abstract An international external quality assurance program on serotyping and antimicrobial susceptibility testing of eight Salmonella enterica strains was performed to enhance the capacity of national and regional reference laboratories in WHO Global Salm-Surv (WHO GSS). In 2002 a total of 117 laboratories from 67 countries participated. For serotyping, almost 90 % of the results were correct. For susceptibility testing, 91 % of the results were in agreement with the expected results, and 86 % of the performed tests with the reference strain E. coli ATCC were inside the quality control range specified by NCCLS guidelines. Comparing the results of EQAS 2002 to the results from 2000 and 2001 showed a clear improvement in the laboratories capacity to accurately serotype and susceptibility test Salmonella. We attribute this improvement to the training provided by WHO GSS, the EQAS and the highquality Salmonella typing antisera, provided to most participants as a part of the WHO GSS. Introduction Salmonella is one of the most important foodborne pathogens worldwide, leading to millions of cases of diarrheal illness each year in developing as well as industrialized countries. Furthermore, there is a growing concern for the increasing resistance to antimicrobial therapies in Salmonella. Recently, the multiresistant Salmonella clone "DT104" has spread among several countries and continents. In addition infections with resistant Salmonella are associated with increased morbidity and mortality. In order to enhance the member countries capacity to detect and respond to Salmonella problems, as well as to improve global surveillance of Salmonella, WHO launched an international Salmonella surveillance and laboratory support project in January 2000, the "WHO Global Salm-Surv". To support laboratories participating in WHO Global Salm-Surv, an External Quality Assurance System (EQAS) has been established. The EQAS supports the assessment of the quality of serotyping and antimicrobial susceptibility testing of Salmonella in participating laboratories. The EQAS program is organised by the (DVI) in collaboration with WHO, Institut Pasteur and Centers for Control and Prevention in Atlanta and has been
2 Pasteur, Health, performed annually since Each EQAS has so far involved serotyping and susceptibility testing of eight Salmonella strains. The first EQAS in 2000 was arranged for only a limited number of WHO Global Salm-Surv laboratories, 44. In 2001 the EQAS covered 103 laboratories and finally the EQAS in 2002 included a total of 117 WHO Global Salm-Surv laboratories. Materials and methods The EQAS was announced on the WHO Global Salm-Surv listserver, and laboratories not previously participating were encouraged to apply. A total of 132 laboratories were enrolled in the EQAS In 2001 an interactive Web database was established for entry of the laboratories test results through a password protected site at the WHO Global Salm-Surv homepage. In 2002 this database was extended to make entry of the answers of an evaluation questionnaire possible as well. Eight Salmonella isolates and an E. coli reference strain were sent to all laboratories. The Salmonella strains represented different serogroups (Table 1) and antimicrobial susceptibility patterns (Table 4). All strains were shipped as stab cultures according to the IATA Dangerous Goods Regulations, 43 rd ed for shipment of infectious substances affecting humans. A test form for results and a questionnaire with general questions about methods, yearly numbers of isolations etc. was enclosed. An evaluation questionnaire and information about username and password for the Web database were sent by together with further information about AWB number, flight company, expected arrival etc. Laboratories were instructed to subculture strains on agar plates as soon as possible after receipt and store them at refrigerator temperature. The test results were requested to be recorded on the attached form and entered within 60 days in the EQAS Web database or sent by fax or to DVI. Participation in the WHO EQAS was free of charge except for each institution s own expenses for analysis. The laboratories were requested to use the serotyping and susceptibility testing methods routinely performed in the laboratory. The strains were tested against as many as possible of the following antimicrobials: Ampicillin (Amp), chloramphenicol (Chl), ciprofloxacin (Cip), gentamicin (Gen), kanamycin (Kan), nalidixic acid (Nal), streptomycin (Str), sulphonamide (Su), tetracycline (Tet), trimethoprim (Tmp) and finally the combination of sulphonamide and trimethoprim (T/S). Immediately after entering the results in the Web database, an individual evaluation report on obtained and expected results with comments to deviating results was generated by Oracle Portal software and displayed on the screen. If a participant was not able to enter the results, this was done by DVI.
3 Pasteur, Health, Results A total of 117 (88.6 %) of 132 laboratories enrolled in the EQAS 2002 reported their results. Of the 15 laboratories not reporting their data, at least four laboratories never received their strains because of problems in customs. The 117 laboratories represented 67 countries: Albania, Argentina, Australia, Bolivia, Bosnia- Herzegovina, Botswana, Brazil, Bulgaria, Cambodia,, Chile, China, Colombia, Costa Rica, Croatia, Cyprus, Czech, Dom. Rep. of Congo,, Ecuador, Estonia, Finland, France, Georgia, Germany, Greece, Hungary, Iceland, India, Indonesia, Ireland, Israel, Italy, Japan, Jordan, Korea, Kuwait, Latvia, Lebanon, Lithuania, Madagascar, Malaysia, Malta, Morocco, Mauritius, Mexico, Moldovia, Netherlands, New Zealand, Oman, Papua New Guinea, Peru, Philippines, Poland, Romania, Senegal, Slovakia, Slovenia, South Africa, Spain, Sri Lanka, Thailand, Tunisia, Turkey, Uruguay, Venezuela and Vietnam. A mean of 1,413 Salmonella strains (range 1-25,976) were analysed yearly in the 63 laboratories who reported their numbers. On average, 82 % (range 0-100%) of the Salmonella strains were serotyped. Serotyping A total of 97 laboratories (82.9 %) performed serotyping. Of these, 78 laboratories (80.4 %) serotyped all eight strains. Nine laboratories performed serogrouping or incomplete typing. Of 723 serotyping results, 648 (89.6 %) were determined correctly. The results of serotyping are given in Table 1. The number of deviations range from 4 % for Salmonella Typhimurium to 17 % for Salmonella Virchow. For the common serotypes Salmonella Typhimurium, Salmonella Derby and Salmonella Enteritidis incorrect results were reported in four, six and seven percent of cases, respectively. With a serotyping reaction of strain WHO3.4 as 1,3,19:g,s,t:- it is not possible to distinguish Salmonella Senftenberg from Salmonella Dessau. In this case it is normal practice to record the result as Salmonella Senftenberg. Therefore, in cases where Salmonella Dessau was reported, results were not recorded as deviations. Of 97 laboratories serotyping, 52 % correctly serotyped all eight strains, and further 32 % had seven or six strains correctly serotyped. Table 2 shows the number of laboratories with respectively 0, 1, 2,..,8 correct serotypings in 2002 compared to previous years.
4 Pasteur, Health, Table 1. List of Salmonella serotypes sent to the participants and number and types of deviations. Strain Correct serotype Labs serotyping the strain % deviations List of deviating results WHO 3.1 Virchow 6,7: r: 1, Infantis 9, Colindale 5, Galiema 1, Senegal 1, Thompson 1 WHO 3.2 Derby 1,4,[5],12: f,g: [1,2] 91 6 Agona 3, Essen 1, Fyris 1, Kiel 1 WHO 3.3 Weltevreden 3,10,[15]: r: z Elisabethville 3, Seegefeld 1, Ughelli 1, Wilmington 1 WHO 3.4 Senftenberg 1,3,19: g,[s],t: Westhampton 6, Catanzaro 1, Maiduguri 1, Kingston 1, Rideau 2, Suberu 1 WHO 3.5 Typhimurium v. Copenhagen 1,4,12: i: 1, Agona 1, Choleraesuis 1, Kingston 1, Lagos 1 WHO 3.6 Manhattan 6,8: d: 1, Blockley 1, Bovismorbificans 1, Duesseldorf 1, Dunkwa 2, Isangi 2, Kottbus 1, Muenchen 2, Newport 1, Yovokome 1 WHO 3.7 Enteritidis 1,9,12,[f]:g,m,[p]: [1,7] 95 7 Dublin 2, Essen 1, Kapemba 1, Nitra 1, Senftenberg 1, Typhimurium 1 WHO 3.8 Bovismorbificans 6,8,20:r,[i]: 1, Hidalgo 1, Hindmarsh 4, Infantis 1, Kentucky 1, Tallahassee 1 Table 2. Number of correct serotypings in relation to number of laboratories for EQAS 2002 compared to previous years. EQAS 2000 EQAS 2001 EQAS 2002 Number Number of laboratories Number of laboratories Number of laboratories of correct serotypes n % n % n % In total N = % N = % N = %
5 Pasteur, Health, Logistic regression analysis was performed to test, whether there was a significant difference in over-all performance between 2001 and Dependent variable was defined as number of laboratories with certain number of correct answers out of total number of participating laboratories. Independent variable was an interaction term between number of correct answers and year of participation. There was a significant increase in number of laboratories correctly identifying all 8 serotypes from 2001 to 2002 (p=0.0437). Antimicrobial susceptibility testing A total of 117 laboratories reported their susceptibility data. Of these, 105 laboratories performed disk diffusion and 6 laboratories MIC-determinations. Six laboratories reported both methods. If testing is correctly standardized and performed, the results for the E. coli ATCC reference strain are supposed to be inside the quality control (QC) ranges specified by NCCLS. In 52 % of the laboratories, all the results for the E. coli reference strain were within range. For the remaining laboratories a mean of 2.5 tests were out of range. QC ranges and number of laboratories inside range compared to previous years are shown in Table 3. Of 1,022 reference tests performed, 86.3 % (882) were within range. Table 3. Results within the NCCLS QC range for reference strain E. coli ATCC Antimicrobial QC range 1 E. coli ATCC MIC (ug/ml) Disks (mm) EQAS 2000 % (N) 3 Laboratories inside QC range EQAS 2001 % (N) 3 EQAS 2002 % (N) 3 Amp (37) 81 (97) 84 (109) Chl (38) 80 (97) 85 (107) Cip (35) 86 (97) 86 (108) Gen (39) 88 (99) 88 (108) Kan (36) 86 (87) 89 (79) Nal (37) 86 (74) 86 (102) Str (36) 88 (81) 89 (82) Su (19) 66 (53) 74 (57) Tet (42) 78 (96) 87 (102) Tmp (31) 78 (50) 89 (66) T/S =0.5/ (90) 88 (102) 1 NCCLS standard, Performance Standards for Antimicrobial Disk and Dilution Susceptibility testing; 12th Informational suppl. NCCLS document M100-S12, Wayne, Pennesylvania. 2 QC range developed by the manufacturer of Sensititre 3 The number of laboratories performing the test
6 Pasteur, Health, The results of antimicrobial susceptibility testing of eight Salmonella strains were categorised as resistant (R), intermediate (I) or susceptible (S) according to the breakpoints normally used in the laboratories. The expected resistance pattern for the strains are listed in Table 4, and the results (percentage of R/I/S) for each strain and antimicrobial are given in Table 5. Table 4. Expected resistance pattern for the Salmonella strains EQAS Strain Resistance pattern Strain Resistance pattern WHO 3.1 Chl Nal Str Su Tet Tmp T/S WHO 3.5 Amp Chl Gen Kan I Nal Str Su Tet Tmp T/S WHO 3.2 Amp Chl Nal Str Su Tet WHO 3.6 None resistance WHO 3.3 Chl Str Su Tet Tmp T/S WHO 3.7 Chl Gen I Str I Su Tet WHO 3.4 Str I *) WHO 3.8 Str Su Tet Tmp T/S *) Intermediary resistance Table 5. Susceptibility test results (% R/I/S) of eight Salmonella strains in 117 laboratories. Strain Amp Chl Cip Gen Kan Nal Str Su Tet Tmp T/S WHO3.1 3/1/96 100/0/0 1/3/96 1/2/97 1/2/96 100/0/0 87/9/3 100/0/0 97/0/3 99/0/1 100/0/0 WHO3.2 98/0/2 100/0/0 1/6/94 1/1/98 2/9/89 99/0/1 95/5/0 100/0/0 95/1/4 0/0/100 40/20/40 WHO3.3 1/2/97 94/4/2 0/1/99 1/1/98 1/1/98 1/1/98 48/43/9 100/0/0 98/1/1 97/1/1 100/0/0 WHO3.4 1/3/96 1/2/97 0/1/99 2/1/97 1/5/94 0/7/93 14/44/42 13/3/83 8/16/76 1/0/99 3/1/96 WHO3.5 96/0/4 98/0/2 1/9/90 67/17/17 66/28/6 98/0/2 79/17/3 100/0/0 99/0/1 94/0/6 98/0/2 WHO3.6 3/1/96 4/1/95 0/1/99 1/0/99 1/4/95 6/6/89 14/41/45 12/3/85 7/13/81 6/0/94 5/1/94 WHO3.7 4/1/95 94/2/4 1/1/98 66/15/19 4/9/88 3/3/94 30/41/29 97/0/3 97/1/2 4/0/96 5/4/91 WHO3.8 6/1/93 3/3/94 0/1/99 2/1/97 1/5/94 3/5/92 91/6/3 100/0/0 98/1/1 99/1/0 99/0/1 Bold: Expected interpretation. Grey cell: < 90 % hit correct interpretation. In total 8,554 antimicrobial susceptibility tests were performed. Of these, 91.2 % (7,799) were in agreement with the expected results, 6.4 % were minor deviations and 2.5 % were major deviations. Results were regarded as deviations if they were incorrectly interpreted as resistant, intermediate or sensitive. I-S or I-R deviations were called minor deviations, while S-R or R-S deviations were called major. In the individual evaluation reports major deviations were further devided into very major (measuring sensitive when resistant) or just major deviations (measuring resistant when sensitive). This further specification is not included in this report. The percentage of major deviations for each antimicrobial agent is shown in Table 6 for year 2002 and previous years. The distribution of laboratories in regard to the number of minor and major deviations is shown in Fig. 1. All in all, 55 laboratories had no major deviations and 5 laboratories had no deviations at all. Six laboratories were responsible for 89 of the 210 major deviations.
7 Pasteur, Health, Table 6. Number of tests and percentage of major deviations for each antimicrobial. Antimicrobial EQAS 2000 EQAS 2001 EQAS 2002 Total no. of determinations % major deviations Total no. of determinations % major deviations Total no. of determinations Amp Chl Cip Gen Kan Nal Str Su Tet Tmp T/S % major deviations No. of laboratories Fig. 1. Distribution of laboratories in regard to minor and major deviations No. of deviations Major deviations Minor deviations Evaluation of the EQAS by participating laboratories The evaluation of the EQAS program was based on a respons of 61 laboratories to the EQAS evaluation questionnaire. Written materials (announcement, welcoming letter, reporting form and individual evaluation reports) were evaluated as satisfactory (5 %), good (42 %) and very good (52 %). Organisation of the EQAS, information describing EQAS and fulfilment of expectations for the participants were evaluated as satisfactory (5 %), good (40 %) or very good (55 %). In addition, 29 % of the laboratories found it important and 71 % found it very important to participate in the EQAS. The Web database was evaluated as satisfactory (8 %), good (35 %) and very good (58 %).
8 Pasteur, Health, Discussion This year more than half of the laboratories (52 %) serotyped all eight strains correctly and further 18 % had only one single serotype deviation. The percentage of correct serotyping results was 90 % compared to 80 % in EQAS These results indicate an improvement in the ability of serotyping compared to last year in spite of increasing difficulty. Improvement is partly believed to be a consequence of providing last years participants in WHO Global Salm-Surv training courses with small amounts of high-quality antisera. Of course, we hope that attendance at the training courses and repeated participation in EQAS also contributed to improving performance of individual laboratories. The percentage of correct antimicrobial susceptibility test results was 91.2 % -exactly the same as last year. Most participants had very few deviations, while a few laboratories had a lot of deviations. In some cases, this could be explained by use of expired disks or use of disks with low potency. Deviations were especially frequent for testing of aminoglycosides, tetracycline and suphonamides. Among others, testing of these antimicrobials is known to be highly influenced by variations in media conditions such as cationic concentration, acidity and agar depth (specified by the NCCLS guidelines). Also misreading of sulphonamide- and trimethoprim results because of the delayed bacterial response to these antimicrobials (viewed as pinpoint growth inside inhibition zone or continuous growth after MIC endpoint) may have influenced the outcome. When performing antimicrobial susceptibility testing, it is very important to include reference strains for internal quality control. The fact that 15 % of the performed tests with the E. coli reference strain were outside the quality control range shows that the tests were not in perfect control in all laboratories. Routine testing of quality control strains in laboratories not using them regularly would probably improve results considerably. In general, laboratories reporting high numbers of strains tested yearly seem to have a better performance compared to laboratories testing only few strains, indicating that routine and experience plays an important role in insuring consistency and quality in the conduct of laboratory tests. We are looking forward to the next round of EQAS in 2003 and hope for just as many participants or even more. We are pleased to experience that participation was regarded as very important by nearly all the participating laboratories.
THE CARE WE PROMISE FACTS AND FIGURES 2017
THE CARE WE PROMISE FACTS AND FIGURES 2017 2 SOS CHILDREN S VILLAGES INTERNATIONAL WHERE WE WORK Facts and Figures 2017 205 58 79 families and transit 31 Foster homes 162 8 3 173 214 2 115 159 136 148
More informationVeterinary and Agrochemical Research Centre
Veterinary and Agrochemical Research Centre Report on susceptibility of Salmonella serotypes in Belgium. P. Butaye Susceptibility of Salmonella strains was assessed by MIC determination using Sensititer
More informationWELLNESS COACHING. Wellness & Personal Fitness Solution Providers
WELLNESS COACHING Wellness & Personal Fitness Solution Providers Introducing Ourselves... We are Personal Wellness Coaches 2 We help people look and feel better by: - Educating on proper nutrition (80%)
More informationTerms and Conditions. VISA Global Customer Assistance Services
Terms and Conditions VISA Global Customer Assistance Services Visa Global Customer Assistance Services (VGCAS) 1 The Visa Global Customer Assistance Services are co-ordinated by the Global Assistance Centre
More informationMain developments in past 24 hours
ECDC DAILY UPDATE Pandemic (H1N1) 2009 Update 02 October 2009, 09:00 hours CEST Main developments in past 24 hours Weekly Influenza Surveillance Overview to be published today; Media highlights and Eurosurveillance
More informationGlobal EHS Resource Center
Global EHS Resource Center Understand environmental and workplace safety requirements that affect your global operations. 800.372.1033 bna.com/gelw Global EHS Resource Center This comprehensive research
More informationWCPT COUNTRY PROFILE December 2017 HUNGARY
WCPT COUNTRY PROFILE December 2017 HUNGARY HUNGARY NUMBERS WCPT Members Practising physical therapists 727 Total number of physical therapist members in your member organisation 4,000 Total number of practising
More informationWCPT COUNTRY PROFILE December 2017 SWEDEN
WCPT COUNTRY PROFILE December 2017 SWEDEN SWEDEN NUMBERS WCPT Members Practising physical therapists 11,043 Total number of physical therapist members in your member organisation 17,906 Total number of
More informationWCPT COUNTRY PROFILE December 2017 SERBIA
WCPT COUNTRY PROFILE December 2017 SERBIA SERBIA NUMBERS WCPT Members Practising physical therapists 622 Total number of physical therapist members in your member organisation 3,323 Total number of practising
More informationCurrent State of Global HIV Care Continua. Reuben Granich 1, Somya Gupta 1, Irene Hall 2, John Aberle-Grasse 2, Shannon Hader 2, Jonathan Mermin 2
Current State of Global HIV Care Continua Reuben Granich 1, Somya Gupta 1, Irene Hall 2, John Aberle-Grasse 2, Shannon Hader 2, Jonathan Mermin 2 1) International Association of Providers of AIDS Care
More informationWELLNESS COACHING. Wellness & Personal Fitness Solution Providers NZ & Australia
WELLNESS COACHING Wellness & Personal Fitness Solution Providers NZ & Australia Introducing Ourselves... We are Personal Wellness Coaches 2 We help people look and feel better by: - Educating on proper
More informationCountry-wise and Item-wise Exports of Animal By Products Value Rs. Lakh Quantity in '000 Unit: Kgs Source: MoC Export Import Data Bank
Country-wise and Item-wise Exports of Animal By Products Value Rs. Lakh Quantity in '000 Unit: Kgs Source: MoC Export Import Data Bank Country CAPEXIL Description HS Code Value 2010-2011 Quantity 2010-2011
More informationESPEN Congress Geneva 2014 FOOD: THE FACTOR RESHAPING THE SIZE OF THE PLANET
ESPEN Congress Geneva 2014 FOOD: THE FACTOR RESHAPING THE SIZE OF THE PLANET Buy 2 and take 3: are we benefitting from cheaper food? P. Marques-Vidal (CH) Pedro Marques-Vidal Department of Internal Medicine
More informationWorld Connections Committee (WCC) Report
World Connections Committee (WCC) Report 06 Co-Dependents Anonymous Service Conference Countries Where CoDA Exists This report reflects the World Connections Committee (WCC) support of the growth and development
More informationSperm donation Oocyte donation. Hong Kong þ Guideline þ þ Hungary þ þ þ þ Israel þ þ þ þ Italy þ þ þ. Germany þ þ þ þ Greece þ þ þ þ
CHAPTER 8: Donation Although there has been a reduction in the use of donor sperm because of ICSI and the impact of the removal of anonymity in some countries (1), sperm donation is still used and has
More informationDrug Prices Report Opioids Retail and wholesale prices * and purity levels,by drug, region and country or territory (prices expressed in US$ )
1 / 11 Region/Subregion/ Country Africa Eastern Africa Kenya Madagascar Mauritius Uganda United Republic of Tanzania Northern Africa Algeria Egypt Libya Morocco Sudan Southern Africa Botswana Burkina Faso
More informationRecommended composition of influenza virus vaccines for use in the 2007 influenza season
Recommended composition of influenza virus vaccines for use in the 2007 influenza season September 2006 This recommendation relates to the composition of vaccines for the forthcoming winter in the southern
More informationCND UNGASS FOLLOW UP
CND UNGASS FOLLOW UP INCB follow-up activities on Chapter 2. Operational recommendations on ensuring the availability of and access to controlled substances exclusively for medical and scientific purposes,
More informationAppendix F: Test-Curriculum Matching Analysis
Appendix F: Test-Curriculum Matching Analysis TIMSS went to great lengths to ensure that comparisons of student achievement across countries would be as fair and equitable as possible. The TIMSS 2015 Assessment
More informationLouisville '19 Attachment #69
Telephone Meeting Approved and why I propose Using zoom to fulfill both Phone and Virtual video meeting Formats. The first established phone meeting Sanctioned by Gamblers Anonymous (listed on Trustee
More informationEU Market Situation for Poultry. Committee for the Common Organisation of the Agricultural Markets 20 April 2017
EU Market Situation for Poultry Committee for the Common Organisation of the Agricultural Markets 2 April 217 -9.% -11.% -5.% -.1% -.7% -2.2% 3.% 1.7% 1.2%.8%.6%.%.%.% 7.9% 7.% 6.4% 6.2% 6.% 5.5% 5.3%
More information3.5 Consumption Annual Prevalence Opiates
3.5 Consumption 3.5.1 Annual Prevalence 3.5.1.1 Opiates EUROPE Western and Central Europe OPIATES AMERICA Central America Estonia, 2004 1.5 Panama** 0.2 Luxembourg, 2000 0.9 Honduras*, 2005 0.2 Latvia,
More informationמדינת ישראל. Tourist Visa Table
Updated 23/05/2017 מדינת ישראל Tourist Visa Table Tourist visa exemption is applied to national and official passports only, and not to other travel documents. Exe = exempted Req = required Press the first
More information- Network for Excellence in Health Innovation
Real-world evidence is evidence from any and all sources of data that may contribute to more effective health care, including health care best tailored to the needs of individual patients. - Network for
More informationPharmaceutical, Medical and Health-related Government and Regulatory bodies around the world.
1 International International Conference on Harmonization (ICH) World Health Organization (WHO) 2 Argentina National Administration of Drugs, Food and medical Technology. Australia s Department of health
More informationIOSH No Time to Lose campaign: working together to tackle asbestos-related cancer #NTTLasbestos. Jonathan Hughes IOSH Vice President
IOSH No Time to Lose campaign: working together to tackle asbestos-related cancer #NTTLasbestos Jonathan Hughes IOSH Vice President About the Institution of Occupational Safety and Health (IOSH) www.iosh.co.uk
More informationGlobal Measles and Rubella Update November 2018
Global Measles and Rubella Update November 218 Measles Number of Reported Measles by WHO Regions 218 Region Member States* Suspected cases Measles cases Clin Epi Lab Jan Feb Mar Apr May Jun Jul Aug Sep
More informationCouncil Officers and Domain Chairs
Agenda Registration - Coffee Welcome Reports from the EACTS Tour of Exhibition and Meeting areas Freight Forwarding, On-site Handling & Access Lunch Housing Exhibition Management and Services Any other
More informationRecommended composition of influenza virus vaccines for use in the 2009 southern hemisphere influenza season
Recommended composition of influenza virus vaccines for use in the 2009 southern hemisphere influenza season The World Health Organization (WHO) convenes technical meetings 1 in February and September
More informationמדינת ישראל. Tourist Visa Table. Tourist visa exemption is applied to national and official passports only, and not to other travel documents.
Updated 25/05/2015 ישראל Tourist Visa Table Tourist visa exemption is applied to national and official passports only, and not to other travel documents. (C) Bearers of official passports requiring tourist
More informationLEBANON. WCPT COUNTRY PROFILE December 2018
LEBANON WCPT COUNTRY PROFILE December 2018 LEBANON NUMBERS 1600 1400 1200 1000 800 600 400 200 0 Physical therapists in the country Members in MO 1,480 1,480 Total PTs in country 800000 700000 600000 500000
More informationPandemic H1N Dr. Maria Neira Global Influenza Programme WHO, Geneva
Pandemic H1N1 2010 Dr. Maria Neira Global Influenza Programme WHO, Geneva WHO Role during pandemic (H1N1) 2009 Under the International Health Regulations (2005) Detect event (notification by Member States
More informationDENMARK. WCPT COUNTRY PROFILE December 2018
DENMARK WCPT COUNTRY PROFILE December 2018 DENMARK NUMBERS 14000 12000 10000 8000 6000 4000 2000 0 Physical therapists in the country Members in MO 11,720 12,975 Total PTs in country 800000 700000 600000
More informationAppendix F. The Test-Curriculum Matching Analysis Science TIMSS 2011 INTERNATIONAL RESULTS IN SCIENCE APPENDIX F 479
Appendix F The Test-Curriculum Matching Analysis Science TIMSS 2011 INTERNATIONAL RESULTS IN SCIENCE APPENDIX F 479 TIMSS went to great lengths to ensure that comparisons of student achievement across
More informationGlobal Measles and Rubella Update. April 2018
Global Measles and Rubella Update April 218 Measles Number of Reported Measles by WHO Regions 218 Region Member States* Suspected cases Measles cases Clin Epi Lab Jan Feb Mar Apr May Jun Jul Aug Sep Oct
More informationThe Test-Curriculum Matching Analysis: Science
Appendix C The Test-Curriculum Matching Analysis: Science TIMSS went to great lengths to ensure that comparisons of student achievement across countries would be as fair and equitable as possible. The
More informationORBE Summary of Benefits
www.wellaway.com ORBE Summary of Benefits www.wellaway.com Summary of Benefits Annual Limit 5,000,000 Coinsurance ORBE 90 ORBE 100 WellAway s share of costs on a covered service Your share of costs on
More informationGERMANY. WCPT COUNTRY PROFILE December 2018
GERMANY WCPT COUNTRY PROFILE December 2018 GERMANY NUMBERS 160000 140000 120000 100000 80000 60000 40000 20000 0 Physical therapists in the country Members in MO 21,502 136,000 Total PTs in country 800000
More informationGlobal Measles and Rubella Update October 2018
Global Measles and Rubella Update October 218 Measles Number of Reported Measles Cases by WHO Regions 218 Region Member States* Suspected cases Measles cases Clin Epi Lab Jan Feb Mar Apr May Jun Jul Aug
More informationUndetectable = Untransmittable. Mariah Wilberg Communications Specialist
Undetectable = Untransmittable Mariah Wilberg Communications Specialist Undetectable=Untransmittable PLWH who get and stay undetectable have effectively no risk of transmitting HIV to their sex partners
More informationLarge observational study to UNderstand the Global impact of Severe Acute respiratory FailurE (LUNG-SAFE)
Large observational study to UNderstand the Global impact of Severe Acute respiratory FailurE (LUNG-SAFE) John Laffey, Giacomo Bellani, Tai Pham, Eddy Fan, Antonio Pesenti on behalf of the LUNG SAFE Investigators
More informationReport on susceptibility of Salmonella serotypes in Belgium Vicky Jasson
CODA-CERVA Report on susceptibility of Salmonella serotypes in Belgium 2014. Vicky Jasson Veterinary and Agrochemical Research Centre 1 Introduction Salmonella is one of the most important bacterial zoonotic
More informationCountry Length Discount Travel Period Anguilla All 20% off 08/24/11 12/15/11 Antigua All 20% off 08/24/11 12/15/11 Argentina All 20% off 08/24/11
Country Length Discount Travel Period Anguilla All 20% off 08/24/11 12/15/11 Antigua All 20% off 08/24/11 12/15/11 Argentina All 20% off 08/24/11 12/15/11 Aruba All 20% off 08/24/11 12/15/11 Australia
More informationThe Global Summit of Women 2009 Santiago, Chile May 14-16
The Global Summit of Women 2009 Santiago, Chile May 14-16 Presentation on Combating Violence Against Women By Susan Arnot Heaney, Global Director, Corporate Responsibility, Avon Products, Inc. (USA) Public
More information3.1 PHASE 2 OF THE GLOBAL PROJECT
RESULTS CHAPTER 3 3.1 PHASE 2 OF THE GLOBAL PROJECT (1996 1999) This new report of the Global Project provides data on anti-tuberculosis drug resistance from 58 geographical settings. Of these, 28 provided
More informationRecommended composition of influenza virus vaccines for use in the influenza season
Recommended composition of influenza virus vaccines for use in the 2009 2010 influenza season February 2009 This recommendation relates to the composition of vaccines for the forthcoming influenza season
More informationSTAT/SOC/CSSS 221 Statistical Concepts and Methods for the Social Sciences. Introduction to Mulitple Regression
STAT/SOC/CSSS 1 Statistical Concepts and Methods for the Social Sciences Introduction to Mulitple Regression Christopher Adolph Department of Political Science and Center for Statistics and the Social
More informationD7.1 Report summarising results of survey of EU countries to identify volumes and trends in relation to the import and export of stem cells
Disclaimer: The content of this Deliverable represents the views of the author only and is his/her sole responsibility; it cannot be considered to reflect the views of the European Commission and/or the
More informationD7.1 Report summarising results of survey of EU countries to identify volumes and trends in relation to the import and export of stem cells
Disclaimer: The content of this Deliverable represents the views of the author only and is his/her sole responsibility; it cannot be considered to reflect the views of the European Commission and/or the
More informationWHO Global Status Report on Alcohol 2004
! Drinking patterns The consumption of alcoholic beverages can be studied from a number of viewpoints, ranging from the viewpoint of an economist to that of a cultural anthropologist. When viewed from
More informationA report on the epidemiology of selected vaccine-preventable diseases in the European Region 30% 20% 10%
% of reported measles cases WHO EpiBrief A report on the epidemiology of selected vaccine-preventable diseases in the European Region No. /17 This issue of WHO EpiBrief provides an overview of selected
More informationEURO POLIO PAGE Data as of 04 October 2005 (Week 38)
World Health Organization Regional Office for Europe EURO POLIO PAGE Data as of 04 October 2005 (Week 38) Vaccine-preventable Diseases and Immunization programme, Division of Technical Support website:
More informationDepartment of Biological Standardisation OMCL Network & Healthcare (DBO)
Department of Biological Standardisation OMCL Network & Healthcare (DBO) Implementation of Pathogen Reduction Technologies for Blood Components for Transfusion: Updated Table 2009-2010 COUNCIL OF EUROPE
More informationCross Border Genetic Testing for Rare Diseases
Cross Border Genetic Testing for Rare Diseases EUCERD Joint Action WP8 Helena Kääriäinen National Institute for Health an Welfare, Helsinki, Finland Starting point Possibilities and demand for genetic
More informationMeasles and rubella monitoring January 2015
Measles and rubella monitoring January 215 Reporting on January December 214 surveillance data and epidemic intelligence data to the end of January 215 Main developments Measles During the 12-month period
More informationTobacco: World Markets and Trade
United States Department of Agriculture Foreign Agricultural Service Circular Series FT -09-05 Sep. 2005 List of Tables Tobacco: World Markets and Trade Table 2 U.S. Tobacco Trade: 2004-2005 Table 3 Unmanufactured
More informationRecommended composition of influenza virus vaccines for use in the influenza season
Recommended composition of influenza virus vaccines for use in the 2006 2007 influenza season This recommendation relates to the composition of vaccines for the forthcoming influenza season in the northern
More informationAPPENDIX II - TABLE 2.3 ANTI-TOBACCO MASS MEDIA CAMPAIGNS
WHO REPORT ON THE GLOBAL TOBACCO EPIDEMIC, 2011 APPENDIX II - TABLE 2.3 ANTI-TOBACCO MASS MEDIA CAMPAIGNS (SEE TABLE 4.9) Africa The Americas South-East Asia Europe Eastern Mediterranean Western Pacific
More informationCALLING ABROAD PRICES FOR EE SMALL BUSINESS PLANS
CALLING ABROAD PRICES FOR EE SMALL BUSINESS PLANS More information about out-of-bundle charges for our small business customers calling internationally from the UK using a small business price plan Page
More informationSponsor Novartis Generic Drug Name. Pimecrolimus. Therapeutic Area of Trial. Atopic dermatitis
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Pimecrolimus Therapeutic Area of Trial Atopic dermatitis Approved Indication U.S. indication: Pimecrolimus cream 1% is indicated
More informationPROMOTION AND PROTECTION OF ALL HUMAN RIGHTS, CIVIL, POLITICAL, ECONOMIC, SOCIAL AND CULTURAL RIGHTS, INCLUDING THE RIGHT TO DEVELOPMENT
UNITED NATIONS A General Assembly Distr. LIMITED A/HRC/11/L.16 16 June 2009 Original: ENGLISH HUMAN RIGHTS COUNCIL Eleventh session Agenda item 3 PROMOTION AND PROTECTION OF ALL HUMAN RIGHTS, CIVIL, POLITICAL,
More informationof the Bone and Joint Decade The Global Challenge of Fragility Fractures and the Role of Fragility fracture Network
of the Bone and Joint Decade The Global Challenge of Fragility Fractures and the Role of Fragility fracture Network The Fragility Fracture Network of the Bone and Joint Decade Mission: To promote globally
More informationWorld Health organization/ International Society of Hypertension (WH0/ISH) risk prediction charts
World Health organization/ International Society of Hypertension (WH0/ISH) risk prediction charts (charts in colour) (These charts will be updated in 2014) 2 1. Introduction 2. Instructions on how to use
More informationThe IB Diploma Programme Statistical Bulletin. November 2015 Examination Session. Education for a better world
The IB Diploma Programme Statistical Bulletin November 2015 Examination Session Education for a better world TheIBDiplomaProgrammeStatisticalBuletin,November2015ExaminationSession. InternationalBaccalaureate
More informationHighlighting in the WHO European Region:
No. 23(April 2012) Issue 15, April 2011 A monthly publication on vaccine preventable diseases and immunization data and analysis Highlighting in the WHO European Region: Update on measles in the European
More informationADMINISTRATIVE AND FINANCIAL MATTERS. Note by the Executive Secretary * CONTENTS. Explanatory notes Tables. 1. Core budget
UNITED NATIONS Distr. GENERAL 13 October 1997 ENGLISH ONLY SUBSIDIARY BODY FOR IMPLEMENTATION Seventh session Bonn, 20-29 October 1997 Item 9 of the provisional agenda ADMINISTRATIVE AND FINANCIAL MATTERS
More informationAlcohol-related harm in Europe and the WHO policy response
Alcohol-related harm in Europe and the WHO policy response Lars Moller Programme Manager World Health Organization Regional Office for Europe Date of presentation NCD global monitoring framework: alcohol-related
More informationDrug resistance TB in People Living with HIV: research questions and priorities.
Drug resistance TB in People Living with HIV: research questions and priorities. Haileyesus Getahun, MD, PhD. Stop TB Department World Health Organisation Geneva, Switzerland Outline of presentation Definition
More informationFOURIER STUDY GREYLOCK PRESS: CTS PRODUCT SAMPLE - FOURIER YES. Did the study achieve its main objective?
FOURIER STUDY Did the study achieve its main objective? 2 15% 1 5% 9.8% YES FOURIER compared Repatha with placebo in patients who were taking a statin and had hardening or narrowing of the arteries and
More informationHighlighting in the WHO European Region: measles outbreaks rubella surveillance acute flaccid paralysis surveillance
No. 17 (September 2011) A monthly publication on vaccine preventable diseases and immunization data and analysis Issue 15, April 2011 Highlighting in the WHO European Region: measles outbreaks rubella
More informationAccess to treatment and disease burden
Access to treatment and disease burden Robert Flisiak Department of Infectious Diseases and Hepatology Medical University in Białystok, Poland Moulin de Vernègues, 27-29 August 2015 Disclosures Advisor
More informationDesign and Analysis of a Cancer Prevention Trial: Plans and Results. Matthew Somerville 09 November 2009
Design and Analysis of a Cancer Prevention Trial: Plans and Results Matthew Somerville 09 November 2009 Overview Objective: Review the planned analyses for a large prostate cancer prevention study and
More informationAnnual prevalence estimates of cannabis use in the late 1990s
Cocaine abuse in most east European countries, by contrast, is still far less widespread and less of a problem. A majority of countries in eastern Europe either did not report on cocaine at all, or they
More informationSummary of Results for Laypersons
What was the Study Called? Summary of Results for Laypersons A Randomized, Double-blind, Parallel-group, Placebo- and Active-controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability
More informationFRAMEWORK CONVENTION ALLIANCE BUILDING SUPPORT FOR TOBACCO CONTROL. Smoke-free. International Status Report
FRAMEWORK CONVENTION ALLIANCE BUILDING SUPPORT FOR TOBACCO CONTROL Smoke-free Environments International Status Report As December, 00 Smoke-free environments are a vital part combating the global tobacco
More informationHighlighting in the WHO European Region: Summary. No. 21(February 2012)
No. 21(February 2012) Issue 15, April 2011 A monthly publication on vaccine preventable diseases and immunization data and analysis Highlighting in the WHO European Region: Update on measles in the European
More informationMen & Health Work. Difference can make a difference Steve Boorman & Ian Banks RSPH Academy 2013
Men & Health Promotion @ Work Difference can make a difference Steve Boorman & Ian Banks RSPH Academy 2013 Difference can make a Difference Mens health: State of mens health Use of services Role of the
More informationGLOBAL FMD SITUATION DURING 2001/2002
APPENDIX 2 GLOBAL FMD SITUATION DURING 2001/2002 Report of the FAO/OIE World Reference Laboratory for FMD, Institute for Animal Health, Ash Road, Pirbright, Woking, Surrey GU24 ONF, United Kingdom Tables
More informationWHO REGIONAL OFFICE FOR EUROPE RECOMMENDATIONS ON INFLUENZA
WHO REGIONAL OFFICE FOR EUROPE RECOMMENDATIONS ON INFLUENZA September 2017 Address requests about publications of the WHO Regional Office for Europe to: Publications WHO Regional Office for Europe Marmorvej
More informationThe Single Convention on Narcotic Drugs- Implementation in Six Countries: Albania, Bangladesh, India, Kyrgyzstan, Sri Lanka, Ukraine
The Single Convention on Narcotic Drugs- Implementation in Six Countries: Albania, Bangladesh, India, Kyrgyzstan, Sri Lanka, Ukraine A MONOGRAPH PREPARED FOR: International Pain Policy Fellowship Training
More informationSmokefree Policies in Europe: Are we there yet?
Smokefree Policies in Europe: Are we there yet? 14 April 2015, 9:00 10:30am Rue de l Industrie 24, 1040 Brussels Permanent Partners: Temporary Partners: The research for the SFP Smokefree Map was partially
More informationGSS to GFN. Dr. Hilde Kruse Programme Manager Food Safety WHO/Europe
GSS to GFN Dr. Hilde Kruse Programme Manager Food Safety WHO/Europe PRESENTATION OUTLINE GSS & GFN: The Basics GSS From Birth to Reincarnation GFN Ever Improving Future Forecast THE BASICS GSS? GFN? WHAT
More informationRECOMMENDATIONS ON INFLUENZA VACCINATION DURING THE WINTER SEASON
RECOMMENDATIONS ON INFLUENZA VACCINATION DURING THE 2018 2019 WINTER SEASON October 2018 Address requests about publications of the WHO Regional Office for Europe to: Publications WHO Regional Office for
More informationGuidance for Travelers on Temporary Work Assignment Abroad
infected person to immediately seek medical care but, prior to arrival, notify their healthcare provider that they may have been exposed to AI. For more information about avian influenza, see www.cdc.gov/flu/avian/facts.htm,
More informationShigellosis SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods
Annual Epidemiological Report for 2016 Shigellosis Key facts Shigellosis is a relatively uncommon disease in the EU/EEA, but remains of concern in some countries and for some population groups. In 2016,
More informationFellowships in nuclear science and technology: Applying the knowledge
Fellowships in nuclear science and technology: Applying the knowledge Nearly 1200 scientists, engineers, and specialists receive training each year under IAEA-supported fellowships and scientific visits
More informationQ1 What age are you?
Q1 What age are you? Answered: 504 Skipped: 0 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 4.56% 23 3.77% 19 4.56% 23 6.15% 31 3.97% 20 6.55% 33 5.95% 30 6.75% 34 6.35% 32 4.37% 22 6.75% 34 5.56%
More informationOverview of drug-induced deaths in Europe - What does the data tell us?
Overview of drug-induced deaths in Europe - What does the data tell us? João Matias, Isabelle Giraudon, Julián Vicente EMCDDA expert group on the key-indicator Drug-related deaths and mortality among drug
More informationMaternal Deaths Disproportionately High in Developing Countries
EMBARGOED until Monday, 20 October, 6am GMT HQ/2003/24 20 October 2003 CF/DOC/PR/2003-82 Maternal Deaths Disproportionately High in Developing Countries African women are 175 times more likely to die in
More informationICM: Trade-offs in the fight against HIV/AIDS
ICM: Trade-offs in the fight against HIV/AIDS 1 As the HIV/AIDS pandemic enters its 25 th year, both the number of infections and number of deaths due to the disease continue to rise. Despite an enormous
More informationField of Post-M.D. Training
TABLE C-1 (GRADUATES OF CANADIAN MEDICAL SCHOOLS) RANK Family Medicine Emergency Medicine (CFPC) Care of the Elderly (CFPC) Enhanced Skills: Other Fam. Med. Training FAMILY MEDICINE SUBTOTAL Anesthesiology
More information